Advanced in Synovial Sarcoma

Dr. Antoni Ribas

Hematology | Oncology
The Regents Of The University Of California
200 Ucla Medical Plz, Suite 165 34, 
Los Angeles, CA 
Offers Telehealth
Advanced in Synovial Sarcoma
The Regents Of The University Of California
200 Ucla Medical Plz, Suite 165 34, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Antoni Ribas is a Hematologist and an Oncologist in Los Angeles, California. Dr. Ribas is rated as an Advanced provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Melanoma, Melanoma of the Eye, Glioma, and Synovial Sarcoma.

His clinical research consists of co-authoring 406 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Synovial Sarcoma.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
200 Ucla Medical Plz, Suite 165 34, Los Angeles, CA 90095
Other Locations
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
900 Weyburn Place, Suite 14 171, Los Angeles, CA 90095
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 210, Santa Monica, CA 90404

Additional Areas of Focus

Dr. Ribas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade
Enrollment Status: Completed
Publish Date: July 30, 2025
Intervention Type: Drug, Biological, Procedure, Other
Study Phase: Phase 1
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Biological, Drug
Study Drugs: LGK974, PDR001
Study Phase: Phase 1
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Biological
Study Drugs: Pembrolizumab, Talimogene Laherparepvec
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma with Innate Anti-PD-1 Resistance
A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma with Innate Anti-PD-1 Resistance
Enrollment Status: Terminated
Publish Date: December 04, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Binimetinib, Nivolumab
Study Phase: Phase 2
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drugs: KPT-9274, Niacin ER, Nivolumab
Study Phase: Phase 1
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Drug
Study Drugs: Spartalizumab, LAG525, Capmatinib, Canakinumab, Ribociclib
Study Phase: Phase 2
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: November 01, 2023
Intervention Type: Biological, Other, Drug, Procedure
Study Drugs: Aldesleukin, Busulfan, Cellular Therapy, Filgrastim, Fludarabine, Plerixafor
Study Phase: Phase 1
A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
Enrollment Status: Terminated
Publish Date: August 03, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 20, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade
Enrollment Status: Terminated
Publish Date: February 28, 2019
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Phase: Phase 1
View 12 Less Clinical Trials

406 Total Publications

Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Journal: Nature medicine
Published: August 26, 2025
Similar Doctors
Elite in Synovial Sarcoma
Dr. Sant P. Chawla
Oncology | Hematology
Elite in Synovial Sarcoma
Dr. Sant P. Chawla
Oncology | Hematology
2811 Wilshire Boulevard, Suite 414, 
Santa Monica, CA 
 (2.5 miles away)
310-552-9999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sant Chawla is a Hematologist and an Oncologist in Santa Monica, California. Dr. Chawla is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma. Dr. Chawla is currently accepting new patients.

Elite in Synovial Sarcoma
Dr. Mark B. Agulnik
Oncology
Elite in Synovial Sarcoma
Dr. Mark B. Agulnik
Oncology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (13.9 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Agulnik is an Oncologist in Los Angeles, California. Dr. Agulnik is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Angiosarcoma, Osteotomy, and Colonoscopy.

Elite in Synovial Sarcoma
Dr. Warren Chow
Hematology | Oncology
Elite in Synovial Sarcoma
Dr. Warren Chow
Hematology | Oncology

Uc Regents

101 The City Dr S, Uci Dept Of Medicine, 
Orange, CA 
 (37.2 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Warren Chow is a Hematologist and an Oncologist in Orange, California. Dr. Chow is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, and Chondrosarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ribas's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile